Cure My Disease

Don't miss your cure!

 Log in / Sign up

Opioid may tame dangerous blood pressure jumps during breathing tube insertion

NCT ID NCT07348159

Symptom relief Sponsor: Dr. Waseem Ullah Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 26, 2026 · Updated 3 times

Summary

This study tested whether nalbuphine, an opioid painkiller, can prevent sudden increases in blood pressure and heart rate when a breathing tube is placed during general anesthesia. 107 adults having elective surgery were randomly given either nalbuphine or a placebo before anesthesia. Researchers measured blood pressure and heart rate at several time points to see if nalbuphine kept these levels more stable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nalbuphine
What this could lead to
If it works, this could give doctors a simple way to keep blood pressure stable during anesthesia, reducing risks for some patients.
What could go wrong
This is a small, completed trial with 107 people. The results may not apply to all patients, and nalbuphine is an opioid with side effects like nausea or drowsiness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

107 people

The number who actually took part.

Started

Mar 2024

Finished

Dec 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Patients scheduled for elective surgery under general anesthesia requiring laryngoscopy and orotracheal intubation. * American Society of Anesthesiologists (ASA) physical status I or II. * Age between 18 and 60 years. * Male and female patients. * Patients who provide written informed consent. Exclusion Criteria * Known hypersensitivity to nalbuphine or any opioids. * History of cardiovascular disease, including uncontrolled hypertension, arrhythmias, or ischemic heart disease. * Respiratory disorders such as asthma, chronic obstructive pulmonary disease, or significant respiratory compromise. * Renal or hepatic impairment. * Pregnancy or lactation. * Use of medications affecting hemodynamic response (e.g., beta-blockers or calcium channel blockers). * Emergency surgery. * Anticipated difficult airway (Mallampati class III or IV).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemodynamic response to laryngoscopy and orotracheal intubation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemodynamic response to laryngoscopy and orotracheal intubation

Contacts and locations

Locations

  • Hayatabad Medical Complex

    Peshawar, Khyber Pakhtunkhwa, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.